Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients

被引：17

作者：

Ady, N

Morat, L

Fizazi, K

Soria, JC

Mathieu, MC

Prapotnich, D

Sabatier, L ^{[1
]}

Chauveinc, L

机构：

[1] DRR DSV, Lab Radiobiol & Oncol, CEA, F-92265 Fontenay Aux Roses, France

[2] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France

[3] Inst Gustave Roussy, Dept Anatomopathol, F-94805 Villejuif, France

[4] Inst Mutualiste Montsouris, Serv Urol, F-75014 Paris, France

[5] Inst Curie, Dept Radiotherapie, F-75005 Paris, France

来源：

BRITISH JOURNAL OF CANCER | 2004年 / 90卷 / 02期

关键词：

HER-2/neu; circulating tumour cells; prostate cancer; metastatic process;

D O I：

10.1038/sj.bjc.6601532

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

HER-2/neu may play a role in prostate carcinogenesis, The aim of this study was to use the expression of HER-2/neu as a molecular marker for the detection of circulating tumour cells (CTCs) in the blood of patients with prostate cancer (PC), Blood samples were collected from 42 patients with PC and nine healthy volunteers. Immunomagnetic beads were used to harvest epithelial cells from peripheral blood mononuclear cells. Total RNA was extracted and reverse transcribed before analysis by real-time PCR with HER-2/ neu-specific primers. CTCs were HER-2/neu positive in six out of 11 (54%) patients with metastatic disease and in three out of 31 (9.6%) patients with localised PC (P = 0,004). In blood samples from nine healthy volunteers, we detected no expression of HER-2/ neu. The present method appears to be minimally invasive, highly sensitive and a specific approach for detecting CTCs in PC. Furthermore, it may help better target HER-2/neu in advanced PC.

引用

页码：443 / 448

页数：6

共 41 条

[1]

Agus DB, 1999, CANCER RES, V59, P4761

[2]

Arai Y, 1997, PROSTATE, V30, P195, DOI 10.1002/(SICI)1097-0045(19970215)30:3<195::AID-PROS8>3.0.CO

[3]

2-L

[4] Detection of circulating prostate cells by reverse transcriptase polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages [J].